Vine Medical, Inc.

Vine Medical Inc., a for-profit medical device manufacturer based in Goleta, California, operates as a federal grant recipient and subrecipient, developing soft robotics technology for emergency airway management. The vendor's federal footprint is narrowly focused: one NSF SBIR Phase I prime grant and five subgrant awards nested under University of California, Santa Barbara as prime grantee, with all recent work directed at advancing a self-deploying endotracheal intubation device toward FDA submission and post-market clinical study.

Vine Medical's customer concentration sits with two federal agencies. The National Science Foundation funded a $274,440 SBIR Phase I (Technology, Innovation, and Partnerships, CFDA 47.084) award dated September 1, 2023, to develop proof-of-concept for a soft robotics system targeting over 90% first-pass intubation success rate without requiring direct visualization. The Defense Health Agency then became the effective customer through five subgrant awards issued to UCSB (December 19, 2023; April 29, 2024; November 6, 2024; March 6, 2025; June 12, 2025), with Vine Medical as subrecipient and technical lead. Across the subgrant awards, Vine Medical drives design freeze and design verification milestones, working alongside UCSB and Stanford to advance technology readiness levels toward TRL 5 and TRL 6, encompassing bench and cadaver testing, design control implementation per 21 CFR 820, ISO 5361 verification, and FDA Q-submission strategy. The combined obligated dollars across all six awards totals $1.8 million.

Vine Medical has not held federal contracts, holds no position on government-wide acquisition vehicles or IDIQs, and operates exclusively within the federal SBIR/STTR grant ecosystem. Activity has remained steady at two awards per year from 2023 through 2025. The vendor competes full-and-open without SBA set-aside designations. Operationally, Vine Medical functions as the technology innovator and manufacturing partner within a UCSB-anchored consortia structure, responsible for device design, regulatory pathway validation, and clinical readiness — a posture typical of medical device ventures in early-stage federal R&D funding rather than operational services or production contracting.